1. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013—process and methods [PMG9]. London: NICE. 2013. https://www.nice.org.uk/article/pmg9/ . Accessed 23 Nov 2016.
2. Pandor A, Stevenson M, Martyn-St James M, Stevens J, Hamilton J, Rawdin A et al. Ponatinib for treating chronic myeloid leukaemia: a single technology Appraisal. School of Health and Related Research (ScHARR). 2016. https://www.nice.org.uk/guidance/ta451/documents/committee-papers Accessed 20 Nov 2017.
3. National Institute for Health and Care Excellence (NICE). Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance. Technology appraisal TA241. London: NICE. 2012. https://www.nice.org.uk/guidance/ta241 . Accessed 23 Nov 2016.
4. Goldman J. Chronic myeloid leukaemia. Medicine. 2009;37(4):195–7.
5. Roman E, Smith A, Appleton S, Crouch S, Kelly R, Kinsey S, et al. Myeloid malignancies in the real-world: occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–2015. Cancer Epidemiol. 2016;42:186–98.